2019 Ocular Hypertension Pipeline ReviewHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)2019 Ocular Hypertension Pipeline ReviewPR NewswireJanuary 1, 2020ReblogShareTweetShareDUBLIN, Dec. 31, 2019 /PRNewswire/ -- The "Ocular Hypertension - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.Research and Markets LogoMoreOcular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular meshwork properly, fluid pressure in the eye builds up, causing ocular hypertension. There are no symptoms with ocular hypertension. Risk factors include age, family history of glaucoma, lower systemic blood pressure, thinner central cornea and bleeding at the optic nerve head. Treatment includes eye drops to reduce intraocular pressure. The Ocular Hypertension - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Ocular Hypertension (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Ocular Hypertension (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 4, 8, 13, 4 and 10 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.Ocular Hypertension (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.ScopeThe pipeline guide provides a snapshot of the global therapeutic landscape of Ocular Hypertension (Ophthalmology). The pipeline guide reviews pipeline therapeutics for Ocular Hypertension (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Ocular Hypertension (Ophthalmology) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Ocular Hypertension (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Ocular Hypertension (Ophthalmology)Key Topics Covered: Ocular Hypertension - Overview Ocular Hypertension - Therapeutics Development Ocular Hypertension - Therapeutics Assessment Ocular Hypertension - Companies Involved in Therapeutics Development Ocular Hypertension - Drug Profiles Ocular Hypertension - Dormant Projects Ocular Hypertension - Discontinued Products Ocular Hypertension - Product Development MilestonesCompanies Mentioned Aerie Pharmaceuticals Inc Allergan Plc Angelini Group Chong Kun Dang Pharmaceutical Corp D. Western Therapeutics Institute Inc Eyenovia Inc Kedalion Therapeutics Inc Laboratorios SALVAT SA Laboratorios Sophia SA de CV Lee's Pharmaceutical Holdings Ltd Neurim Pharmaceuticals Ltd NicOx SA Novartis AG Ocular Therapeutix Inc Ocuphire Pharma Inc Santen Pharmaceutical Co Ltd Senju Pharmaceutical Co Ltd Sun Pharma Advanced Research Company Ltd Sylentis SAU Taejoon Pharm Co Ltd Takeda Pharmaceutical Co LtdFor more information about this drug pipelines report visit https://www.researchandmarkets.com/r/fr8ryvAbout ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.Media Contact:Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716CisionMoreView original content:http://www.prnewswire.com/news-releases/2019-ocular-hypertension-pipeline-review-300980115.htmlSOURCE Research and MarketsReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextThis Is Why Your Eyes Get So Red—and How to Prevent ItWho What WearRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoDollar stumbles as coronavirus ramps up Fed cut betsReutersDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchMost face masks won’t protect you from the coronavirusYahoo FinanceStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance Video'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceBankrupt Boy Scouts may need to sell Norman Rockwell art to pay sexual abuse victimsUSA TODAYBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo Finance